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Abstract  Diabetes mellitus (DM) patients are at an increased risk of acute myocardial infarction (AMI). Adequate 
DM control may reduce in-hospital mortality and cardio-pulmonary complications after an AMI. The objective of 
this study was to determine whether uncontrolled DM in patients with an incidental AMI was associated with an 
increased risk of in-hospital mortality and selected cardio-pulmonary complications. A secondary data analysis of 
the Puerto Rican Cardiovascular Surveillance System during 2007, 2009, and 2011 was conducted. The study 
included men and women living in Puerto Rico who were hospitalized due to an incidental AMI and had information 
on HbA1c measurement (n=220). Patients were divided according to their HbA1c levels into two groups (i) <7% 
(controlled); and (ii) >7% (uncontrolled). Mortality and complications were defined according to ICD-9 codes. 
Univariate and multivariate logistic regression models were used to test for associations between HbA1c and 
mortality and cardio-pulmonary outcomes. The model was adjusted for gender, obesity (BMI >30kg/m2), 
hyperlipidemia, hypertension, chronic obstructive pulmonary disease, smoking, insurance and age. The results 
revealed no statistically significant association between the controlled and the uncontrolled DM patients and 
mortality, respectively cardiopulmonary complications (unadjusted OR 2.1; 95% CI: 0.7-6.4; adjusted OR 2.4; 95% 
CI: 0.5-10.5). The uncontrolled DM group was statistically significantly younger than those with controlled DM 
(mean age 65.2 vs. 71.1 years; p-value 0.002). There was no statistically significant difference in the prevalence of 
uncontrolled DM between patients with complications (80%) and those without complication (66%; p=value 0.203). 
AMI patients with uncontrolled DM did not have an increased risk of mortality and cardiopulmonary complications 
compared to patients with controlled DM.  This needs further evaluation in a larger study population and DM 
patients with an AMI should have HbA1c measured to estimate their risk of complications. 
Keywords: Diabetes, acute myocardial infarction, mortality, cardiopulmonary complications, glycosylated 
hemoglobin (HbA1c)  
Cite This Article: Romina Altamirano, Michael Caponigro, Gabriela Carrion, Juan Carlos Zevallos, Grettel 
Castro, Juan A. González Sánchez, and Noël C. Barengo, “Incidence of Acute Myocardial Infarction in Patients 
with Diabetes and Its Association with Mortality and Cardiopulmonary Complications in Puerto Rico.” American 
Journal of Public Health Research, vol. 4, no. 6 (2016): 196-201. doi: 10.12691/ajphr-4-6-1. 
1. Introduction 
Diabetes mellitus (DM) is a growing epidemic that has 
affected people from all regions and has become a rising 
global burden [1]. It has affected the health condition of 
millions as well as developed into a financial liability 
internationally. In 2015 there was an estimated 415 
million people with DM and over 5 millions deaths due to 
the disease [1,2]. This chronic condition seems to affect 
all systems of the body, but the most common cause of 
death and disability was due to cardiovascular disease [1]. 
People with DM have a higher prevalence of coronary 
artery disease (CAD) leading to an increased risk of 
myocardial infarction (MI), mortality, and other 
cardiopulmonary complications. The National Cholesterol 
Education Program report from the United States and 
European guidelines consider DM to be a coronary heart 
disease (CHD) equivalent, thereby elevating it to the 
highest risk category [1]. This classification was based on 
coronary mortality for patients with DM without a prior 
MI and patients without DM who had a prior MI [2]. 
According to the American Diabetes Association (ADA) 
[4], the assessment of HbA1c levels in diabetes patients are 
categorized as good control (<7%), suboptimal control 
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(HbA1c 7% to 9%), or poor control (HbA1c >9%)4. Poor 
long-term glycemic control is an important risk factor for 
adverse outcomes in patients with DM [4]. Epidemiologic 
studies suggest that an increase in HbA1c of 1% is 
associated with a 20% increased risk in subsequent 
mortality for patients with coronary disease and 
concurrent DM [4]. Information regarding associations 
between DM control and 30 days in-hospital survival are 
contradictory [5,8,9]. Previous studies had controversial 
results with several limitations that included selection bias 
[6], small sample size causing low power to detect 
differences, and focus on special subgroups of the 
population [12]. 
The aim of our study was to investigate whether 
diabetes control was associated with mortality and 
cardiopulmonary complications such as atrial fibrillation, 
ventricular tachycardia, ventricular fibrillation, cardiac 
arrest, pulmonary infarction, pulmonary edema, 
respiratory failure, and stroke in DM patient with an 
incident AMI in Puerto Rico.  
2. Materials and Methods  
2.1. Study Design 
We conducted a cross-sectional study of the Puerto 
Rican Cardiovascular Surveillance database during 2007, 
2009 and 2011 [10].  
2.2. Study Population 
All previous health records were reviewed before 
including a patient. The definition used in this study as 
inclusion criteria for T2DM was previous history of DM 
found in the medical records according to the ADA. After 
a patient was found to have the diagnosis of T2DM, the 
record was reviewed to see if HbA1c levels were recorded 
to be included in the study. Only those with HbA1c 
measurements taken within the first 24 hours were 
included. The inclusion criteria for an AMI was that each 
case was validated using the widely accepted diagnostic 
definition developed by the World Health Organization 
(WHO) [4] This definition requires that at least two out of 
three criteria be present for the confirmation of AMI. This 
uses information from the patient’s clinical history, serum 
enzyme elevations, and serial ECG findings. This 
secondary data analysis was conducted in patients 
presenting with an incidental (first time) AMI who had 
HbA1c measures taken within the first 24 hours of hospital 
admission and reported in the medical chart. We included 
all patients with ICD-9 codes: 410-414; specifically: New 
MI, 411: Other acute/sub-acute forms ischemic heart 
disease, 412: Old MI, 413 Angina pectoris, and 414: Other 
forms of chronic ischemic heart disease, and excluded 412: 
patients with previous MI. The records of any previous 
hospitalizations for cardiovascular events were reviewed 
when available and if past records indicated similar 
presentation they were excluded from the study. We 
excluded patients who did not meet the diagnosis criteria 
for DM (n=1,138) as stated above, missing key variables 
of the study, had ECG changes consistent with previous 
MI, documented history of MI, patients who developed 
AMI from any procedural events during their hospital stay,  
 
and any cardiopulmonary complication the arises after 24 
hours of initial hospital arrival. The cardiopulomanary 
complications that were included in our study was atrial 
fibrillation, ventricular tachycardia, ventricular fibrillation, 
cardiac arrest, pulmonary infarction, pulmonary edema, 
respiratory failure, and stroke. All of these complications 
were documented in the patient’s medical chart and had to 
be within 24 hours of admission The study population 
consisted of Puerto Ricans (a mostly Hispanic population) 
men and women with T2DM living on the Island who 
were hospitalized for an incidental AMI.  In the database, 
there were 2,204 patients with an AMI during 2007, 2009, 
and 2011. A total of 1,470 patients were excluded for not 
having an incidental AMI or not being diagnosed with 
T2DM. Out of the remaining 734 patients, 532 were 
excluded, as they did not have information on HbA1c 
measurement. Thus, 202 patients comprised our study 
population [10]. 
The study population was divided into two groups 
according to their HbA1C level: controlled DM (HbA1c <7) 
and uncontrolled DM (HbA1c >7). The covariables that 
were analyzed in this study were age, gender, 
hypertension, obesity (defined as BMI>30kg/m2), 
hyperlipidemia, chronic obstructive pulmonary disease 
(COPD), current cigarette smokers, and insurance status. 
These variables were selected because they were related to 
both HbA1c levels as well as to AMI complications.  
All data were obtained from medical documentation of 
each individual patient that was entered into the database 
system. Participants have been appropriately de-identified 
to maintain minimal risk exposure of sensitive information, 
which was our main concern when obtaining the data for 
our study.  
2.3. Statistical Analysis 
STATA version 14.0 was used for the statistical 
analysis. The medical records of patients discharged with 
a diagnosis consistent with AMI were reviewed utilizing a 
standardized electronic data abstraction form, which has 
been adapted to use in Puerto Rico from the Worcester 
Heart Failure Study. Data were captured electronically 
utilizing the REDCapTM web application exclusively 
designed for research studies that allows secure online 
management of surveys and databases. For the purpose of 
present analysis, patients were divided into controlled 
(HbA1c ≤7%) and uncontrolled DM (, HbA1c >7%) based 
on admission HbA1c. Categorical variables are presented 
as percentage and number of patients and the continuous 
variable are presented as mean ± standard deviation. 
Baseline characteristics of the two groups were compared 
using the χ2 test, t student test, and the Fisher exact test as 
appropriate. Logistic regression models (univariate and 
multivariate analysis) were used to test the association 
between the independent variable and the outcome variable, 
which is in-hospital mortality and cardiopulmonary 
complications. The Hosmer-Lemeshow test was used to 
test for the goodness-of-fit of the logistic regression 
models. The multivariate logistic regression model was 
adjusted for sex, age, body mass index (BMI), 
hypertension, hyperlipidemia, chronic obstructive 
pulmonary disease (COPD), current smokers, insurance 
status, and age. A p-value <0.05 was considered as 
statistically significant. 
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3. Results 
Table 1 presents the characteristics of the study 
participants according to DM control (HbA1C<7% versus 
HbA1C≥7%). The only characteristic that was statistically 
significantly different was that the patients in the 
uncontrolled DM group were younger than those in the 
group with controlled DM (mean age 65.2 vs. 71.1 years; 
p-value 0.002). No statistically significant differences 
were found in the distribution of gender, obesity 
(BMI>30kg/m2), hyperlipidemia, hypertension, COPD, 
current smokers, or insurance between the two groups. 
The association between HbA1c, mortality and  
cardio-pulmonary complications among DM patients are 
presented in Table 2. In the univariate analysis 
uncontrolled DM patients were twice as likely to die or to 
have complications than those that had DM controlled 
(OR 2.1; 95% CI: 0.7-6.4). After adjustment for gender, 
BMI>30 kg/m2, hyperlipidemia, hypertension, COPD, 
current smokers, insurance status, and age the OR only 
marginally changed and remained statistically non-
significant (OR 2.4; 95% CI: 0.5-10.3). The OR for an 
association between obesity and mortality was not 
statistically significant after multivariate adjustment (OR 
0.8; 95% CI 0.2-2.8). 
Table 1. Characteristics of diabetes mellitus (DM) patients with first time acute myocardial infarction according to DM control in Puerto Rico 
during 2007, 2009, and 2011 
Characteristics Controlled (HbA1C<7%) % (n) 
Uncontrolled (HbA1C≥7%) 
% (n) p-value 
Sex  % (n 0.112 
Male 47.0 (31) 58.8 (80)  
Female 53.0 (35) 41.2 (56)  
BMI1 >30 kg/m2   0.109 
No 37.0 (17) 24.3 (27)  
Yes 63.0 (29) 75.7 (84)  
Hyperlipidemia   0.413 
No 63.1 (41) 68.9 (93)  
Yes 37.0 (24) 31.1 (42)  
Hypertension   0.526 
No 18.2 (12) 14.7 (20)  
Yes 81.8 (54) 85.3 (116)  
COPD2   0.315 
No 93.9 (62) 89.6 (121)  
Yes 6.1 (4) 10.4 (14)  
Current Smoker   0.564 
No 86.2 (56) 83.0 (112)  
Yes 13.9 (9) 17.0 (23)  
Insurance   0.128 
No 30.3 (20) 20.6 (28)  
Yes 70.0 (46) 79.4 (108)  
    Age (years)- mean (SD3) 71.1 (10.7) 65.2 (12.0) 0.002 
1Body Mass Index; 2Chronic Obstructive Pulmonary Disease; 3Standard Deviation. 
Table 2. Unadjusted and adjusted odds ratios for the association between HbA1c, mortality and complications among diabetes mellitus patients 
with first time acute myocardial infarction in Puerto Rico during 2007, 2009, and 2011 
Characteristics Unadjusted model (n=202) OR (95% CI) 
Adjusted model (n=202) 
OR  (95% CI) 
HbA1c   
Control Reference Reference 
Uncontrolled 2.1 (0.7-6.4) 2.4 (0.5-10.3) 
Sex   
Male Reference Reference 
Female 1.2 (0.5-3.1) 1.7 (0.5-5.6) 
BMI1> 30 kg/m2   
No Reference Reference 
Yes 0.8 (0.3-2.6) 0.8 (0.2-2.8) 
Hyperlipidemia   
No Reference Reference 
Yes 1.5 (0.6-4.0) 2.0 (0.6-6.8) 
Hypertension   
No Reference Reference 
Yes 1.1 (0.3-4.0) 0.7 (0.1-3.6) 
COPD2   
No Reference Reference 
Yes 0.5 (0.07-4.3) 0.3 (0.03-3.0) 
Current Smoker  
No Reference Reference 
Yes 1.4 (0.4-4.4) 2.6 (0.6-12.3) 
Insurance   
Yes Reference Reference 
No 0.8 (0.2-2.5) 0.7 (0.2-3.1) 
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Out of 734 DM patients with an AMI, only 202 had 
their HbA1c levels measured (Table 3). DM patients 
without HbA1C measurement seemed to have a higher 
prevalence of mortality and complications (12.8%) 
compared to measured patients (9.9%). However, these 
results were not statistically significant (p=0.283). There 
was a higher prevalence of COPD in the group where 
HbA1c was measured (9.0%) compared to those with no 
HbA1c measured (4.7%; p-value=0.031). Furthermore, the 
prevalence of obesity (BMI>30 kg/m2) was higher in the 
group who had HbA1c measured (71.9%) compared to 
those who were not measured (62.8%; p-value=0.037). 
There was a higher distribution of patients with insurance 
in the group where HbA1c was measured (76.2%) 
compared to those who did not have measurement (66.4%; 
p-value=0.010). There was no statistical significant 
difference in the rest of the characteristics studied. 
Table 3. Characteristics of all previously diabetes mellitus patients with first time acute myocardial infarction according to whether HbA1C 
was measured or not in Puerto Rico during 2007, 2009, and 2011 
Characteristics HbA1c measured (N=202 % (n) 
No HbA1c measured (N=532) 
% (n) p-value 
Mortality and complications   0.283 
No 90.1 (182) 87.2 (464)  
Yes 9.9 (20) 12.8 (68)  
Sex   0.670 
Male 54.9 (111) 53.2 (283)  
Female 45.1 (91) 46.8 (249)  
BMI1 > 30 kg/m2   0.037 
No 28.0 (44) 37.3 (165)  
Yes 71.9 (113) 62.8 (278)  
Hyperlipidemia   0.951 
No 67.0 (134) 67.2 (353)  
Yes 33.0 (66) 32.8 (172)  
Hypertension   0.642 
No 15.8 (32) 14.5 (77)  
Yes 84.8 (170) 85.5 (455)  
COPD2   0.031 
No 91.0 (183) 95.3 (503)  
Yes 9.0 (18) 4.7 (25)  
Current Smoker   0.113 
No 84.0 (168) 88.4 (465)  
Yes 16.0 (32) 11.6 (61)  
Insurance   0.010 
No 23.8 (48) 33.7 (179)  
Yes 76.2 (154) 66.4 (353)  
Age-mean (SD3)  67.0 (11.9) 67.9 (12.3) 0.430 
1Body Mass Index; 2Chronic Obstructive Pulmonary Disease; 3Standard Deviation. 
4. Discussion 
Even though our study found that AMI patients with 
uncontrolled DM had a two-fold increased risk of 
mortality and cardiopulmonary complications compared to 
controlled DM, this risk increase was not statistically 
significant.  
A possible explanation may be a power issue and future 
studies may adjust for this with a larger study population. 
This may reveal whether poor DM control is associated 
with in-hospital mortality and cardio-pulmonary 
complications. The assessment of chronic glycemic 
control is highly variable among patients with AMIs and 
DM. Because much of this variability occurs at the 
hospital level, the evaluation of DM control could 
represent an additional quality indicator and an 
opportunity to advance patient-centered AMI care [4]. 
Every year over 735,000 Americans citizens have an AMI 
and people with known DM have an increased risk [6,7]. 
In addition, it might be desirable to achieve HbA1c as 
close to the normal glycemic range as possible [8].  
Poor DM control has shown to increase the risk of 
mortality through several mechanisms [11]. When glucose 
levels are chronically elevated they damage blood vessels 
and make them more susceptible to atherosclerosis build 
up. This causes people to develop atherosclerosis at an 
early age, leading to hypertension and coronary artery 
disease [4]. DM patients are also more prone to develop 
dyslipidemia. Their LDL particles are smaller then non-
diabetics making it easier to penetrate vessels. This makes 
the particles more susceptible to oxidation and damage [4]. 
Higher HbA1c was associated with poor glycol-metabolic 
control, older patients, obesity, hypertension, Killip's 
class>1, tachycardia, initial bundle branch block, atrial 
fibrillation, and higher mortality during follow-up 
[5].  These patients with disturbed glucose metabolism 
had worse early outcomes, characterized by progressive 
increased rates of in-hospital mortality according to HbA1c. 
In hospital mortality was 14% higher in patients with 
HbA1c >6.4% [7]. Diabetes patients with low or high 
HbA1c are at higher risk of all cause mortality compared 
wit patients with relatively moderate Hba1c levels [8]. This 
compared to our study by looking for similar outcomes in 
terms of mortality and cardiopulmonary complications. 
Our study also tried to looks for an increased risk of 
mortality and cardiopulmonary complications based on 
Hba1c levels. But our odds ratio was not statistically 
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significant and we had a wide confidence interval showing 
a lack of precision in our study.  
Previous studies have shown that elevated glucose 
levels increase the risk of mortality after an AMI in both 
diabetic and non-diabetic patients [17]. Both DM and non-
DM patients had significantly higher plasma glucose 
levels, while HbA1c-adjusted levels were not associated 
with post-AMI prognosis [19]. Our study did not analyze 
admission glucose but rather HbA1c levels within 24 hours 
of admission. We did not find any significant evidence to 
support the claim that DM patients with AMI had 
increased mortality and complications. We also did not 
evaluate medical records past the initial 24 hours of 
hospital stay to evaluate long-term prognosis for patients 
with controlled and uncontrolled HbA1c levels. A 
secondary data analysis of The National Cardiovascular 
Data Registry (NCDR) observed no association between 
HbA1C and mortality in patients with diabetes presenting 
with AMI [18]. In a multivariable regression, they 
observed no association between low or high HbA1c [18]. 
Similar to their study we did not find any statistically 
significant association between HbA1c and mortality and 
complications. As their study, our study had similar 
limitations DM patients with AMI did not have 
information on HbA1c measurement (59%). In another 
study Hba1c and blood glucose was measured within 3 
hours of admission of an AMI to evaluate for myocardial 
perfusion abnormalities [15]. Patients with the highest 
HbA1c (>8.5%) showed the highest morality, double-
vessel, and triple-vessel disease compared to lower HbA1c 
levels. We had similar outcomes in terms of mortality and 
trying to relate it to chronic glycemic control [19]. But this 
study had a follow up at four weeks and did not accurately 
measure the immediate outcome for elevated HbA1c levels 
as our study did. We also did not find any statistically 
significant association between HbA1c and mortality as 
this study did at the 4 week follow up. To detect 
myocardial perfusion defects and relate it to mortality a 
coronary angiography performed within 24 hours would 
have been a better predictor to relate it to plasma glucose, 
HbA1c, and mortality. Some studies used a different 
definition of DM control [14,15] as our study used HbA1c 
above 7% as uncontrolled DM, while their study used 8.5%.  
The limitations of our study were small sample size and 
limited number of outcomes. Out of a potential 2,204 
patients with an AMI, only 202 had DM and HbA1c 
measured within 24 hours of hospital admission. This 
affected the power of our study to detect an association.  
Since there was a low study population we completed a 
non-responder analysis based on whether HbA1c was 
measured (Table three). The results indeed showed that 
the non-measured HbA1c patients had different profile 
than those with measured HbA1c. The patients with HbA1c 
measured were statistically significantly different in terms 
of BMI>30 kg/m2 (p-value 0.037), have COPD (p-value 
0.031), and have insurance (p-value 0.010) In addition to 
small sample size we also had a limited number of 
outcomes. Out of the 202 patients in our study population, 
only 20 cases had complications. If a greater number of 
complications were found in a study population it could 
possibly change future management strategies for DM 
patients with AMI. Despite not measuring glucose levels, 
hyperglycemia could also affect mortality both acutely 
and chronically. Follow up HbA1c levels should have been 
checked at monthly or yearly intervals to look for a 
possible association with mortality, as it might be a 
predictor of future mortality rather than short-term 
prognosis. Finally, we were not able to assess whether 
hypertension treatment or adecuate hypertension control 
was associated with mortality due to a lack of this 
particular information. Even though we did not find a 
statistically significantly increased risk of being classified 
as hypertensive, we are aware that due to the above 
mentioned limitation, no conclusions can be made in 
regard to a possible association between uncontrolled 
hypertension and mortality 
5. Conclusion 
In conclusion, our findings suggest that AMI patients 
with uncontrolled DM did not have an increased risk of 
mortality and cardiopulmonary complications compared to 
controlled DM. However, this needs further evaluation on 
a larger study population in order to give more accurate 
results evaluate DM patients. We recommend that all DM 
patients with an AMI should have HbA1c measured to 
estimate their risk, manage patient’s glycemic control 
better, and possibly prevent future complications from 
happening. In addition, other factors such as tobacco 
consumption, hyperlipidemia, obesity, and hypertension 
are important factors to be assessed and controlled for in 
order to improve survival in AIM.” 
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